COMPANY
CRISPR Therapeutics
Depending on the program, we take either an ex vivo approach, in which we edit cells outside of the human body before administering them to the patient, or an in vivo editing approach, where we deliver the CRISPR-based therapeutic directly to target cells within the human body. From public records Source · Feb 12, 2026
Hiring
| Title | Location (from posting) | Employer posted | First seen |
|---|---|---|---|
| Quality Site Head | Framingham, MA | Not stated | Oct 5, 2026 |
| Research Associate II, CRISPR-X | San Francisco, CA | Not stated | Oct 5, 2026 |
| Scientist II, CRISPR-X - Gene Insertion | South Boston, MA | Not stated | Oct 5, 2026 |
| Engineer III, mRNA Process Development-Downstream | South Boston, MA | Not stated | Oct 5, 2026 |
| Scientist II, in vivo Gene Insertion | San Francisco, CA | Not stated | Oct 5, 2026 |
Timeline
- Trial start Phase 1/Phase 2: A Trial Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of CTX460 in Adults With Emphysema Associated With Severe Alpha-1 Antitrypsin Deficiency source ↗
- Board tracked Radar started tracking this company’s job board (14 open jobs at last check). source ↗
- Trial start Phase 1/Phase 2: A Safety and Efficacy Study Evaluating CTX112 in Subjects With Refractory Neurologic Autoimmune Disease source ↗
- Trial start Phase 1/Phase 2: A Trial Evaluating Safety, Tolerability and Efficacy of CTX340 in Participants With Hypertension source ↗
- Trial start Phase 1/Phase 2: Safety and Preliminary Efficacy of CTX112 in Adult Participants With Relapsed/Refractory Hematologic Autoimmune Disease source ↗
- Debt Debt: $550M (not counted as a raise), announced Mar 11, 2026. Source: SEC filing. source ↗
- Trial start Phase 1: A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease source ↗
- Trial start Phase 1/Phase 2: A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed/Refractory Hematologic Malignancies source ↗
- Trial start Phase 1: A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias source ↗
- Trial start —: A Long-term Follow-up Study of Subjects Who Received CRISPR CAR T Cellular Therapies source ↗
- Trial start Phase 1/Phase 2: A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors source ↗
- Trial start Phase 1/Phase 2: A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies source ↗
- Trial start Phase 1: An Open-Label, FIH Study Evaluating the Safety, Tolerability, and Efficacy of VCTX211 Combination Product in Subjects With T1D source ↗
- Trial start Phase 1: An Open-Label, FIH Study Evaluating the Safety and Tolerability of VCTX210A Combination Product in Subjects With T1D source ↗
- Trial start Phase 1: A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory T or B Cell Malignancies (COBALT-LYM) source ↗
- Trial start Phase 1: A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory Renal Cell Carcinoma (COBALT-RCC) source ↗
- Trial start Phase 1: A Safety and Efficacy Study Evaluating CTX120 in Subjects With Relapsed or Refractory Multiple Myeloma source ↗
- Trial start Phase 1/Phase 2: A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refractory B-Cell Malignancies (CARBON) source ↗
Upcoming milestones
- 2027-06 (ESTIMATED) · Phase 1 · A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias · NCT07491172
- Jul 1, 2028 (ESTIMATED) · Phase 1/Phase 2 · A Trial Evaluating Safety, Tolerability and Efficacy of CTX340 in Participants With Hypertension · NCT07758634
- Dec 30, 2029 (ESTIMATED) · Phase 1/Phase 2 · A Safety and Efficacy Study Evaluating CTX112 in Subjects With Refractory Neurologic Autoimmune Disease · NCT07804004
- 2030-01 (ESTIMATED) · Phase 1/Phase 2 · A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies · NCT05643742
- Jun 30, 2030 (ESTIMATED) · Phase 1/Phase 2 · A Trial Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of CTX460 in Adults With Emphysema Associated With Severe Alpha-1 Antitrypsin Deficiency (AATD) · NCT07850076
- Dec 31, 2031 (ESTIMATED) · Phase 1 · A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease · NCT06925542
- 2033-12 (ESTIMATED) · Phase 1/Phase 2 · Safety and Preliminary Efficacy of CTX112 in Adult Participants With Relapsed/Refractory Hematologic Autoimmune Disease · NCT07549698
- 2038-08 (ESTIMATED) · · A Long-term Follow-up Study of Subjects Who Received CRISPR CAR T Cellular Therapies · NCT06208878
Open jobs 14
| Title | Location (from posting, not HQ) | Employer posted | First seen | Level |
|---|---|---|---|---|
| Quality Site Head | Framingham, MA | Not stated | Oct 5, 2026 | Senior |
| Research Associate II, CRISPR-X | San Francisco, CA | Not stated | Oct 5, 2026 | Mid |
| Scientist II, CRISPR-X - Gene Insertion | South Boston, MA | Not stated | Oct 5, 2026 | Mid |
| Engineer III, mRNA Process Development-Downstream | South Boston, MA | Not stated | Oct 5, 2026 | Mid |
| Scientist II, in vivo Gene Insertion | San Francisco, CA | Not stated | Oct 5, 2026 | Mid |
| Senior Manager, Program Management | South Boston, MA | Not stated | Oct 5, 2026 | Senior |
| Statistical Programming Contractor (16-Month Contract) | South Boston, MA | Not stated | Oct 5, 2026 | Mid |
| Associate Manager, CMC Operations | South Boston, MA | Not stated | Oct 5, 2026 | Mid |
| Senior Specialist, Site Supply Chain Planning | Framingham, MA | Not stated | Oct 5, 2026 | Senior |
| Senior Scientist, Analytical Development | South Boston, MA | Not stated | Oct 5, 2026 | Senior |
| Associate Director, Regulatory Affairs CMC | South Boston, MA | Not stated | Oct 5, 2026 | Senior |
| Executive Director, Clinical Development | South Boston, MA | Not stated | Oct 5, 2026 | Executive |
| Director, LNP Discovery | South Boston, MA | Not stated | Oct 5, 2026 | Senior |
| Executive Director, External Manufacturing & Supply Chain | South Boston, MA | Not stated | Oct 5, 2026 | Executive |
Funding
- Debt: $550M (not counted as a raise), announced Mar 11, 2026. Source: SEC filing. source ↗
Clinical trials (lead sponsor) 16
| Record | Title | Phase | Status | Start | Primary completion |
|---|---|---|---|---|---|
| NCT07850076 | A Trial Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of CTX460 in Adults With Emphysema Associated With Severe Alpha-1 Antitrypsin Deficiency (AATD) | Phase 1/Phase 2 | Not yet recruiting | Oct 31, 2026 | Jun 30, 2030 (estimated) |
| NCT06208878 | A Long-term Follow-up Study of Subjects Who Received CRISPR CAR T Cellular Therapies | Not listed | Enrolling by invitation | Nov 22, 2023 | 2038-08 (estimated) |
| NCT07549698 | Safety and Preliminary Efficacy of CTX112 in Adult Participants With Relapsed/Refractory Hematologic Autoimmune Disease | Phase 1/Phase 2 | Recruiting | Jul 17, 2026 | 2033-12 (estimated) |
| NCT07491172 | A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias | Phase 1 | Recruiting | Jun 21, 2024 | 2027-06 (estimated) |
| NCT07804004 | A Safety and Efficacy Study Evaluating CTX112 in Subjects With Refractory Neurologic Autoimmune Disease | Phase 1/Phase 2 | Not yet recruiting | Sep 15, 2026 | Dec 30, 2029 (estimated) |
| NCT06925542 | A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease | Phase 1 | Recruiting | Mar 10, 2025 | Dec 31, 2031 (estimated) |
| NCT07758634 | A Trial Evaluating Safety, Tolerability and Efficacy of CTX340 in Participants With Hypertension | Phase 1/Phase 2 | Recruiting | Aug 8, 2026 | Jul 1, 2028 (estimated) |
| NCT05565248 | An Open-Label, FIH Study Evaluating the Safety, Tolerability, and Efficacy of VCTX211 Combination Product in Subjects With T1D | Phase 1 | Terminated | Jan 20, 2023 | Aug 8, 2025 (actual) |
| NCT06492304 | A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed/Refractory Hematologic Malignancies | Phase 1/Phase 2 | Completed | Aug 13, 2024 | Mar 11, 2026 (actual) |
| NCT05795595 | A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors | Phase 1/Phase 2 | Completed | Mar 13, 2023 | Sep 18, 2025 (actual) |
| NCT05643742 | A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies | Phase 1/Phase 2 | Recruiting | Mar 10, 2023 | 2030-01 (estimated) |
| NCT04035434 | A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refractory B-Cell Malignancies (CARBON) | Phase 1/Phase 2 | Terminated | Jul 22, 2019 | Oct 4, 2024 (actual) |
| NCT04438083 | A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory Renal Cell Carcinoma (COBALT-RCC) | Phase 1 | Terminated | Jun 16, 2020 | Oct 8, 2024 (actual) |
| NCT04502446 | A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory T or B Cell Malignancies (COBALT-LYM) | Phase 1 | Terminated | Jul 31, 2020 | Aug 30, 2024 (actual) |
| NCT04244656 | A Safety and Efficacy Study Evaluating CTX120 in Subjects With Relapsed or Refractory Multiple Myeloma | Phase 1 | Terminated | Jan 22, 2020 | Jan 4, 2024 (actual) |
| NCT05210530 | An Open-Label, FIH Study Evaluating the Safety and Tolerability of VCTX210A Combination Product in Subjects With T1D | Phase 1 | Completed | Jan 24, 2022 | Jan 19, 2023 (actual) |
Connect
See your connections at CRISPR Therapeutics on LinkedIn (search by name, results not checked)